Dose Escalation Proceeding: dosing of 2nd dose cohort complete; no drug-related severe adverse events were observed, enabling enrollment of the next higher dose cohort with the goal of establishing ...
Tumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV relapsed/refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback